246 related articles for article (PubMed ID: 24281461)
1. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial.
Lazzerini M; Martelossi S; Magazzù G; Pellegrino S; Lucanto MC; Barabino A; Calvi A; Arrigo S; Lionetti P; Lorusso M; Mangiantini F; Fontana M; Zuin G; Palla G; Maggiore G; Bramuzzo M; Pellegrin MC; Maschio M; Villanacci V; Manenti S; Decorti G; De Iudicibus S; Paparazzo R; Montico M; Ventura A
JAMA; 2013 Nov; 310(20):2164-73. PubMed ID: 24281461
[TBL] [Abstract][Full Text] [Related]
2. Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial.
Lazzerini M; Martelossi S; Magazzù G; Pellegrino S; Lucanto MC; Barabino A; Calvi A; Arrigo S; Lionetti P; Lorusso M; Mangiantini F; Fontana M; Zuin G; Palla G; Maggiore G; Bramuzzo M; Pellegrin MC; Maschio M; Villanacci V; Manenti S; Decorti G; De Iudicibus S; Paparazzo R; Montico M; Ventura A
Inflamm Bowel Dis; 2015 Aug; 21(8):1739-49. PubMed ID: 26185909
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab.
Felipez LM; Gokhale R; Tierney MP; Kirschner BS
J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):28-33. PubMed ID: 21681114
[TBL] [Abstract][Full Text] [Related]
4. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis.
Droitcourt C; Rybojad M; Porcher R; Juillard C; Cosnes A; Joly P; Lacour JP; D'Incan M; Dupin N; Sassolas B; Misery L; Chevrant-Breton J; Lebrun-Vignes B; Desseaux K; Valeyre D; Revuz J; Tazi A; Chosidow O; Dupuy A
Chest; 2014 Oct; 146(4):1046-1054. PubMed ID: 24945194
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
[TBL] [Abstract][Full Text] [Related]
6. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
7. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
Kierkuś J; Iwańczak B; Wegner A; Dadalski M; Grzybowska-Chlebowczyk U; Łazowska I; Maślana J; Toporowska-Kowalska E; Czaja-Bulsa G; Mierzwa G; Korczowski B; Czkwianianc E; Żabka A; Szymańska E; Krzesiek E; Więcek S; Sładek M
J Pediatr Gastroenterol Nutr; 2015 May; 60(5):580-5. PubMed ID: 25564804
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide.
Lazzerini M; Villanacci V; Pellegrin MC; Martelossi S; Magazzù G; Pellegrino S; Lucanto MC; Barabino A; Calvi A; Arrigo S; Lionetti P; Fontana M; Zuin G; Maggiore G; Bramuzzo M; Maschio M; Salemme M; Manenti S; Lorenzi L; Decorti G; Montico M; Ventura A
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1382-1389.e1. PubMed ID: 28286192
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results.
Lazzerini M; Martelossi S; Marchetti F; Scabar A; Bradaschia F; Ronfani L; Ventura A
Aliment Pharmacol Ther; 2007 Feb; 25(4):419-27. PubMed ID: 17269997
[TBL] [Abstract][Full Text] [Related]
12. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review.
Scribano ML; Cantoro L; Marrollo M; Cosintino R; Kohn A
J Clin Gastroenterol; 2014 Jul; 48(6):530-3. PubMed ID: 24667589
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues.
Weiss B; Lerner A; Shapiro R; Broide E; Levine A; Fradkin A; Bujanover Y
J Pediatr Gastroenterol Nutr; 2009 May; 48(5):526-30. PubMed ID: 19412004
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.
Facchini S; Candusso M; Martelossi S; Liubich M; Panfili E; Ventura A
J Pediatr Gastroenterol Nutr; 2001 Feb; 32(2):178-81. PubMed ID: 11321389
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide improves clinical remission in children with Crohn's disease.
Harbour S; Brown N
Arch Dis Child Educ Pract Ed; 2015 Apr; 100(2):111. PubMed ID: 25721487
[No Abstract] [Full Text] [Related]
17. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease.
Mansfield JC; Parkes M; Hawthorne AB; Forbes A; Probert CS; Perowne RC; Cooper A; Zeldis JB; Manning DC; Hawkey CJ
Aliment Pharmacol Ther; 2007 Aug; 26(3):421-30. PubMed ID: 17635377
[TBL] [Abstract][Full Text] [Related]
18. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials.
Feagan BG; Sandborn WJ; Mittmann U; Bar-Meir S; D'Haens G; Bradette M; Cohen A; Dallaire C; Ponich TP; McDonald JW; Hébuterne X; Paré P; Klvana P; Niv Y; Ardizzone S; Alexeeva O; Rostom A; Kiudelis G; Spleiss J; Gilgen D; Vandervoort MK; Wong CJ; Zou GY; Donner A; Rutgeerts P
JAMA; 2008 Apr; 299(14):1690-7. PubMed ID: 18398081
[TBL] [Abstract][Full Text] [Related]
19. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
Feagan BG; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Koval J; Wong CJ; Hopkins M; Hanauer SB; McDonald JW
N Engl J Med; 2000 Jun; 342(22):1627-32. PubMed ID: 10833208
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis.
Wang L; Hong Y; Wu J; Leung YK; Huang Y
World J Gastroenterol; 2017 Nov; 23(43):7727-7734. PubMed ID: 29209113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
